Biotech Values

[DewDiligence]

>COR – Dew, why would you think there's a possibility of no interest in CX717 for ADHD?<

Obviously, there isn’t any now, but I question whether there ever was.

When a biotech executive says “there is strong partnership interest in our drug and we’ve received multiple term sheets,” it should be greeted by investors with skepticism. When an executive says this repeatedly over the course of several years in reference to the same program, it should be greeted by investors with extreme skepticism.